2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 468

Angiotensin II Exacerbates Bone Destruction in TNF-Transgenic Arthritis Mice

Rheumatoid Arthritis – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 130

Anti-CCP Status Determines the Power Doppler Oscillation Pattern in Rheumatoid Arthritis – a Prospective Study

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 503

Anti-CCP Titer and Prevalence Is Influenced By Age at Rheumatoid Arthritis Onset- Analysis Based on a Nationwide Database in Japan

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 574

Anti-CCP3.1 and Anti-CCP3-IgA Antibodies Are Associated with Increasing Age in Subjects without Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 576

Anti-CCP3.1 and Anti-CCP3-IgA Are Elevated in RA-Free Subjects with Idiopathic Pulmonary Fibrosis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 491

Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 512

Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 247

ANTI-Interleukin 1 Therapy in FMF Amyloidosis: A Single Center Experience

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 126

Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort

Healthcare Disparities in Rheumatology - Poster I

9:00AM-11:00AM: Abstract Number: 572

Anti-Periodontal Bacteria Antibody Titers Are Inversely Correlated with ACPA in RA-Free Individuals with Periodontal Disease Compared to Community Controls

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 752

Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 707

Anti-TNF Drugs Are Not Associated with Increasead Risk of Hzv Infections in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 285

Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

9:00AM-11:00AM: Abstract Number: 374

Anxiolytic Effects of the Novel α2δ Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia

Pain – Basic and Clinical Aspects - Poster

9:00AM-11:00AM: Abstract Number: 250

Application of the 2016 European Leage Against Rheumatism (EULAR) /American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) Classification Criteria of Macrophage Activation Syndrome in Patients with Adult Onset Still’s Disease

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

«Previous Page
1
…
4
5
6
7
8
…
70
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].